campesterol has been researched along with dalcetrapib in 2 studies
| Studies (campesterol) | Trials (campesterol) | Recent Studies (post-2010) (campesterol) | Studies (dalcetrapib) | Trials (dalcetrapib) | Recent Studies (post-2010) (dalcetrapib) |
|---|---|---|---|---|---|
| 410 | 75 | 166 | 166 | 38 | 103 |
| Protein | Taxonomy | campesterol (IC50) | dalcetrapib (IC50) |
|---|---|---|---|
| Cholesteryl ester transfer protein | Homo sapiens (human) | 4.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blum, D; Chaput, E; Derks, M; Kallend, D; Niesor, EJ; Staempfli, A | 1 |
| Bentley, D; Kallend, D; Kastelein, JJ; Kees Hovingh, G; Niesor, EJ; Stroes, ES | 1 |
2 trial(s) available for campesterol and dalcetrapib
| Article | Year |
|---|---|
Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Biomarkers; Cholestanol; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Cross-Over Studies; Desmosterol; Esters; Ezetimibe; Homeostasis; Humans; Intestinal Absorption; Lipid Metabolism; Male; Mesocricetus; Models, Animal; Phytosterols; Quinolines; Sitosterols; Sulfhydryl Compounds; Switzerland | 2011 |
Treatment of low HDL-C subjects with the CETP modulator dalcetrapib increases plasma campesterol only in those without ABCA1 and/or ApoA1 mutations.
Topics: Amides; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cross-Over Studies; Double-Blind Method; Esters; Humans; Hypoalphalipoproteinemias; Mutation; Phytosterols; Sulfhydryl Compounds; Treatment Outcome | 2014 |